# Illumina’s SpliceAI2 Finds 17% More Rare-Disease Variants

Published 2026-10-10 · AI.info Team · AI.info

> Illumina’s SpliceAI2 model identified 17% more disease-relevant splice variants than other tested splicing models in a rare-disease research dataset, the company says. A preprint reports the comparison used 7,504 probands and found 133 excess panel-matched variants for SpliceAI2 versus 114 for the next-best model at a fixed odds ratio of 2.

[Illumina](https://assets.illumina.com/content/dam/illumina-marketing/images/genomics-research/articles/spliceai2/SpliceAI2.pdf) says its new genomic AI model found 17% more disease-associated splice variants than other tested prediction models in an analysis of rare-disease cases. Announced October 8, 2026, SpliceAI2 predicts how DNA changes affect RNA splicing—the process cells use to assemble RNA transcripts before making proteins. The results come from a preprint by Illumina’s BioInsight AI Lab, and the company labels the model for research use only, not diagnostic procedures.

## What the 17% gain measures

The researchers analyzed whole-genome and phenotype data from 7,504 probands in the Genomics England 100,000 Genomes Project. They assigned disease-associated genes based on participants’ phenotypes and shuffled those phenotype assignments to estimate the background rate of variants matching disease-associated genes. The researchers compared the odds ratio of that match with the number of excess matching variants across different score thresholds. At a fixed odds ratio of 2, SpliceAI2 recovered 133 excess variants, compared with 114 for the next-best model. Those figures amount to roughly 17% more for SpliceAI2, consistent with the percentage Illumina reported.

That comparison does not mean 17% more patients received a diagnosis. The paper estimates that cryptic splice variants identified by SpliceAI2 account for an additional 15% of excess genetic burden beyond protein-truncating variants in its analysis. About half of the prioritized cryptic splice variants lay more than 50 bases into introns, locations that exome sequencing would typically miss.

> “Application to a rare disease cohort reveals that predicted splice-altering variants are highly enriched in disease-associated genes and account for 15% of the excess genetic burden, with approximately half residing in deep intronic regions likely missed by exome sequencing.”
>
> Kishore Jaganathan, Kyle Kai-How Farh and their coauthors write in the preprint.

## SpliceAI2 predicts more than splice sites

The first SpliceAI, released in 2019, predicts whether a position in a gene is likely to function as a splice site. SpliceAI2 also predicts how splice sites connect and which full-length RNA transcript forms those connections produce. It takes DNA sequence as input, allowing researchers to study potential transcript changes without first obtaining RNA from the tissue where a gene is active.

The model was trained on splice-site and splice-junction measurements from 314,745 RNA-sequencing samples across humans and nine other mammalian species. For transcript prediction, the team also used 330 long-read RNA-sequencing samples. On held-out genes, SpliceAI2 reconstructed the most abundant transcript correctly 82% of the time, compared with 78% when trained without the long-read data.

The preprint also reports comparisons with SpliceAI, Pangolin and AlphaGenome across several variant-effect benchmarks, including cryptic splice-site detection, quantitative trait loci and reporter assays. In one benchmark based on RNA-sequencing data, the model outperformed the other tested models in predicting activation of cryptic splice sites by rare variants. The authors also analyzed population-genomics data and protein measurements, reporting that predicted splice disruption was associated with lower protein abundance among carriers of rare splice-region variants.

## Research access, with limits

SpliceAI2 is available through Illumina’s BioInsight applications, including DRAGEN Annotation and Emedgene. Source code, trained models and precomputed variant predictions are also available on [GitHub](https://ai.info/companies/github), according to the company’s research article. The original SpliceAI has been cited in more than 3,400 publications, according to Illumina.

The preprint identifies a remaining challenge: predicting how a variant’s effect changes across tissues, cell types and developmental contexts. The paper reports that differences in baseline splicing between tissues were predictive of tissue-specific variant effects, while tissue-specific predictions did not add further benefit in that analysis.

## Sources

1. Original source [Illumina · page 1](https://assets.illumina.com/content/dam/illumina-marketing/images/genomics-research/articles/spliceai2/SpliceAI2.pdf) assets.illumina.com

Other pages read

2. [Illumina · Press release details](https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=29236) illumina.com
3. [Illumina · Introducing spliceai2 the next generation of splicing and t…](https://www.illumina.com/science/genomics-research/articles/introducing-spliceai2--the-next-generation-of-splicing-and-trans.html) illumina.com

## Related stories

- [Illumina says its AI model won Arc's virtual cell challenge](https://ai.info/news/illumina-cellularai-virtual-cell-challenge)
- [DeepMind Maps 9 Billion Human DNA Variants With AlphaGenome](https://ai.info/news/deepmind-maps-9-billion-human-dna-variants-with-alphagenome)
- [Google Study Finds AI Raises Patent Quality but Splits Skill Gains](https://ai.info/news/google-ai-patent-lawyers-skill-gains-study)
- [Anthropic Cuts Live Internet Access to All Internal Evaluations](https://ai.info/news/anthropic-cuts-live-internet-access-internal-evaluations)
- [GPT-5 Help Cut Persistence on Follow-Up Tasks](https://ai.info/news/gpt-5-help-cut-persistence-follow-up-tasks)

## Explore

[More articles](https://ai.info/news)

---

Canonical: https://ai.info/news/illumina-spliceai2-17-percent-more-rare-disease-variants
